Omega-3 Fatty Acids: EPA, DHA, ALA Conversion Rates, Best Sources and Optimal Dosage

ALA is an 18-carbon omega-3 fatty acid found in flaxseed, chia seeds, hemp seeds, walnuts and canola oil. It is an essential fatty acid — the body cannot synthesise it — but its primary physiological role is as a substrate for conversion to the longer-chain EPA (20 carbons) and DHA (22 carbons), which are the metabolically active forms. The problem is that this conversion is extremely inefficient. Studies using isotope-labelled ALA consistently show that humans convert approximately 5–10 % of ALA to EPA, and only 0.5–5 % reaches DHA. The conversion bottleneck occurs at the delta-6 desaturase enzyme, which is slow, shared with omega-6 metabolism (linoleic acid competes for the same enzyme), and further suppressed by alcohol consumption, smoking, ageing, and certain nutrient deficiencies (zinc, pyridoxine, magnesium). Practically, this means that consuming flaxseed oil as your only omega-3 source provides minimal EPA and negligible DHA — a fact of particular clinical significance for vegans and vegetarians who do not eat fish. EPA and DHA are found preformed in marine foods: oily fish (sardines, mackerel, salmon, anchovies, herring), shellfish, and algae — the primary marine producers of these fatty acids (fish accumulate EPA and DHA by eating algae or eating creatures that ate algae). Algal oil supplements are the most direct way for those avoiding fish to obtain preformed DHA and EPA, bypassing the inefficient conversion pathway entirely.

EPA and DHA exert their anti-inflammatory effects through several overlapping mechanisms. The most well-characterised is competitive inhibition of arachidonic acid (AA) in eicosanoid synthesis. AA, derived from the omega-6 fatty acid linoleic acid, is the precursor for pro-inflammatory eicosanoids: prostaglandins of the 2-series (e.g. PGE2), thromboxanes of the 2-series (TXA2, a potent platelet aggregator), and 4-series leukotrienes (LTB4, a neutrophil chemotactic agent). EPA, when present in membrane phospholipids, competes with AA as a substrate for the enzymes cyclooxygenase (COX) and lipoxygenase (LOX), producing instead 3-series prostaglandins and 5-series leukotrienes — which are substantially less inflammatory and in many cases functionally antagonistic to the 2-series and 4-series products. DHA gives rise to an additional class of specialised pro-resolving mediators (SPMs): resolvins (specifically the D-series resolvins), protectins and maresins. These are not simply less inflammatory — they are actively pro-resolution, meaning they accelerate the clearance of inflammatory cells from tissues and promote return to homeostasis. This distinction matters clinically: suppressing inflammation initiation (as NSAIDs do) is pharmacologically different from facilitating resolution, and the SPM pathway offers a mechanistically distinct target. EPA also reduces VLDL synthesis in the liver and increases hepatic beta-oxidation of fatty acids, which partly explains its triglyceride-lowering effects. The landmark REDUCE-IT trial (2019) demonstrated a 25 % reduction in major cardiovascular events with 4 g/day of icosapentaenoic acid (EPA-only) in people with elevated triglycerides and existing cardiovascular disease — findings that shifted clinical cardiology guidelines.

Omega-3 fatty acids are highly polyunsaturated — multiple double bonds make them exquisitely susceptible to oxidation. Lipid oxidation produces peroxides, aldehydes (including 4-hydroxynonenal and malondialdehyde) and other reactive compounds that are biologically harmful and associated with inflammation at high concentrations — the precise opposite of the intended effect. Multiple independent analyses of commercially available fish oil supplements have found that a substantial proportion — estimates ranging from 20 % to over 50 % of tested products — exceed recommended oxidation thresholds (typically expressed as peroxide value, anisidine value, or the TOTOX score). Sources of oxidation include: raw material quality (smaller, fresher fish oxidise less; heat-exposed bulk oil oxidises rapidly during processing), inadequate nitrogen blanketing during manufacturing, transparent packaging, light exposure during retail display, consumer storage at room temperature for months after opening, and failure to include adequate antioxidants (tocopherols, astaxanthin). Rancid fish oil does not merely fail to deliver benefits — there is evidence from in vitro and animal studies that oxidised fish oil may actually promote rather than reduce inflammation. Key practical guidance: buy capsules that are opaque or in dark glass; check the TOTOX score if the manufacturer publishes it (a TOTOX below 10 is excellent; above 26 is the maximum permissible under most standards); cut a capsule open and smell it — a strong fishy or paint-like odour indicates significant oxidation; store opened bottles in the refrigerator; and use within 3 months of opening. Triglyceride-form fish oils (re-esterified from ethyl esters) are better absorbed and tend to be more stable than ethyl ester forms, though they are more expensive.

Dosing recommendations vary by clinical context. For general cardioprotection in healthy individuals, the European Society of Cardiology and American Heart Association recommend 250–500 mg of combined EPA + DHA per day, achievable through two portions of oily fish per week. For people with existing cardiovascular disease or elevated triglycerides, clinical guidelines support 1–4 g per day of EPA + DHA. The REDUCE-IT trial used 4 g/day of pure EPA; the earlier ORIGIN trial used 840 mg/day of EPA + DHA and found no cardiovascular benefit — suggesting that dose matters enormously and that results from lower-dose trials should not be extrapolated to higher-dose applications. For anti-inflammatory purposes (joint inflammation, inflammatory conditions), doses of 2–4 g/day of combined EPA + DHA are commonly used in clinical practice, with EPA emphasised over DHA for inflammatory endpoints. For brain health and cognitive function, DHA is the dominant species in neuronal membranes, and observational data associate higher DHA intake with reduced risk of Alzheimer's disease, though RCT data in this area remain mixed. During pregnancy, DHA is critical for fetal brain and retinal development — a minimum of 200 mg DHA daily is widely recommended for pregnant women, and the European Food Safety Authority recommends 100–200 mg additional DHA above normal adult intake. The therapeutic index of omega-3 supplementation is generally good: doses up to 5 g/day appear safe for most people, though high doses may modestly increase LDL-C, have mild anticoagulant effects (relevant for those on anticoagulant medications), and may cause gastrointestinal discomfort.

The most EPA + DHA per gram of food comes from small oily fish: sardines (approximately 2 g EPA + DHA per 100 g), mackerel (2.5 g), wild salmon (1.5–2.5 g), anchovies (2 g), and herring (1.5–2 g). Farmed salmon EPA + DHA content has declined significantly over the past decade as manufacturers have replaced marine-derived feed components with vegetable oils — a consequence worth noting when choosing between wild and farmed. Tuna provides EPA + DHA but at lower concentrations (0.2–0.5 g per 100 g for canned tuna), and also carries methylmercury concerns that are relevant for pregnant women and young children. Shellfish — mussels, oysters, and clams — are excellent and underappreciated sources of EPA and DHA (0.5–1 g per 100 g), and also provide zinc, iodine, selenium and B12. Plant sources provide only ALA: flaxseed (22 g ALA per 100 g — by far the richest plant source), chia seeds (18 g/100 g), hemp seeds (8 g/100 g), and walnuts (9 g/100 g). Given the conversion limitations described above, these should be viewed as ALA sources, not EPA/DHA sources. For vegans seeking EPA and DHA without supplementation, seaweed provides trace amounts, but algal oil is the only realistic food-equivalent source of meaningful DHA and EPA for those not consuming fish.